Our results describe a new mechanism by which bort suppresses self‐renewal of LSC by NF‐ĸB‐dependent inhibition of CDK6 in MLL‐arranged leukaemia, indicating that bort might be a potential drug for AML patients with MLL rearrangements. The gene discussed is KMT2A; the disease is leukemia.